Hospital
Watsonville Hospital Corporation
Watsonville Hospital Corporation was paid $23.00M by Medicaid between Jan 2018 and Feb 2024, across 191 billing codes. Its largest line is 99281, Emergency department visit for the evaluation and management, self-limited or minor — 30% of everything it billed.
33Billing provider infoWATSONVILLE HOSPITAL CORPORATION
WATSONVILLE, CA 95076
WATSONVILLE, CA 95076
33aNPI1710958228assigned 02/01/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$23.00M
24GClaims537,230
24DCodes billed191
24AFirst – last monthJan 2018 – Feb 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#111 of 410
Median peer was paid$6.90M
This provider vs. median3.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 102,224 | $3.86M | |
| 2019 | 104,387 | $4.03M | |
| 2020 | 74,487 | $3.23M | |
| 2021 | 91,905 | $4.08M | |
| 2022 | 111,527 | $5.25M | |
| 2023 | 52,570 | $2.55M | |
| 2024incomplete | 130 | $4K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 30% | 86,106 | 76,764 | $6.88M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.6% | 4,244 | 4,160 | $1.06M |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 4.4% | 7,099 | 7,094 | $1.01M |
| 70450 | Computed tomography, head or brain; without contrast material | 3.5% | 4,352 | 4,241 | $806K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.2% | 9,635 | 9,010 | $740K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 2.8% | 9,534 | 9,140 | $633K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.2% | 12,829 | 11,384 | $503K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | 2.1% | 4,975 | 4,949 | $472K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.0% | 9,597 | 8,981 | $452K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.9% | 4,298 | 4,051 | $426K |
| Z7502 | 1.6% | 9,886 | 9,684 | $367K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | 1.6% | 3,149 | 3,018 | $366K |
179 more codes
| 96375 | Therapeutic injection; each additional sequential IV push | 1.6% | 6,763 | $357K |
| 80053 | Comprehensive metabolic panel | 1.5% | 25,565 | $340K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.5% | 4,856 | $335K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.4% | 9,294 | $315K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.3% | 3,797 | $302K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 1.3% | 3,560 | $302K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.2% | 28,098 | $274K |
| 99213 | Doctor's office visit, returning patient (routine) | 1.1% | 1,653 | $264K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 1.1% | 6,556 | $260K |
| 76830 | Ultrasound, transvaginal | 1.1% | 3,018 | $254K |
| 77063 | Screening digital breast tomosynthesis, bilateral | 1.1% | 6,818 | $247K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | 1.1% | 460 | $245K |
| 97535 | Self-care/home management training, each 15 minutes | 1.1% | 7,237 | $244K |
| 71046 | Radiologic examination, chest; 2 views | 1.0% | 10,766 | $231K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.0% | 2,366 | $230K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,855 | $216K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 316 | $203K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 652 | $178K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 280 | $172K |
| 93976 | <1% | 587 | $155K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 785 | $151K |
| 93971 | <1% | 1,069 | $141K | |
| 59025 | Fetal non-stress test | <1% | 2,538 | $131K |
| 76770 | <1% | 1,428 | $127K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,112 | $125K |
| T1999 | Miscellaneous therapeutic items and supplies, retail purchases, not otherwise classified; identify product in "remarks" | <1% | 59,762 | $119K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,157 | $116K |
| 76642 | <1% | 1,578 | $113K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,447 | $112K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 10,266 | $107K |
| V5008 | Hearing screening | <1% | 1,498 | $104K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,540 | $91K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,557 | $87K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 180 | $84K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 1,133 | $84K |
| 81025 | <1% | 8,412 | $78K | |
| 84484 | <1% | 5,634 | $78K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,858 | $75K |
| 83690 | <1% | 8,463 | $73K | |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 3,270 | $69K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,433 | $68K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,317 | $67K |
| 83605 | <1% | 4,719 | $66K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 282 | $62K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 220 | $62K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 995 | $61K |
| 73562 | <1% | 2,086 | $59K | |
| 81001 | <1% | 14,372 | $58K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 206 | $58K |
| 73610 | <1% | 1,653 | $57K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 1,663 | $52K |
| 73030 | <1% | 1,641 | $52K | |
| 73630 | <1% | 1,474 | $48K | |
| 72110 | <1% | 733 | $39K | |
| 86141 | <1% | 2,569 | $37K | |
| 0450 | Emergency room services | <1% | 888 | $37K |
| 73130 | <1% | 1,020 | $36K | |
| 73564 | <1% | 1,069 | $36K | |
| 87040 | <1% | 2,522 | $36K | |
| 87186 | <1% | 2,997 | $35K | |
| 71045 | Radiologic examination, chest; single view | <1% | 3,442 | $35K |
| Z7610 | <1% | 2,889 | $33K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,436 | $30K |
| 73110 | <1% | 886 | $30K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,263 | $30K |
| 99156 | <1% | 473 | $29K | |
| 77066 | Tomosynthesis, mammo | <1% | 171 | $28K |
| 87077 | <1% | 2,926 | $28K | |
| 77065 | Tomosynthesis, mammo | <1% | 242 | $27K |
| 87634 | <1% | 281 | $25K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 252 | $24K |
| 83880 | <1% | 872 | $24K | |
| 83735 | <1% | 2,835 | $24K | |
| 72100 | <1% | 667 | $23K | |
| 82962 | <1% | 5,670 | $23K | |
| 93017 | <1% | 441 | $23K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 779 | $23K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 781 | $23K |
| 81002 | <1% | 5,066 | $23K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 785 | $23K |
| 76801 | <1% | 264 | $22K | |
| 76536 | <1% | 279 | $20K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 82 | $20K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 2,274 | $20K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,254 | $18K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,823 | $18K |
| 80061 | Lipid panel | <1% | 954 | $17K |
| 73502 | <1% | 567 | $17K | |
| 84702 | <1% | 838 | $17K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,938 | $17K |
| 74018 | <1% | 665 | $16K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,070 | $16K |
| 73080 | <1% | 440 | $16K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,433 | $15K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,350 | $15K |
| 86403 | <1% | 514 | $15K | |
| 85379 | <1% | 1,031 | $13K | |
| 87400 | <1% | 1,661 | $11K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 118 | $11K |
| 90715 | <1% | 203 | $10K | |
| 82652 | <1% | 201 | $10K | |
| 85610 | <1% | 1,998 | $10K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 98 | $9K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,166 | $9K |
| Z9725 | <1% | 189 | $8K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 2,115 | $8K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 573 | $7K |
| 82570 | <1% | 950 | $7K | |
| 86901 | <1% | 1,709 | $7K | |
| 77080 | <1% | 153 | $7K | |
| 80069 | <1% | 544 | $6K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 66 | $6K |
| 86850 | <1% | 539 | $6K | |
| 84466 | <1% | 330 | $6K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 626 | $6K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 470 | $5K |
| 85730 | <1% | 738 | $5K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 471 | $5K |
| 82728 | <1% | 274 | $5K | |
| 93350 | <1% | 53 | $4K | |
| 73140 | <1% | 191 | $4K | |
| 72050 | <1% | 94 | $4K | |
| 82247 | <1% | 523 | $4K | |
| 93970 | <1% | 25 | $4K | |
| 87420 | <1% | 201 | $4K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 187 | $3K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 429 | $3K |
| 84156 | <1% | 718 | $3K | |
| 83540 | <1% | 331 | $3K | |
| 87088 | <1% | 225 | $3K | |
| 86900 | <1% | 651 | $2K | |
| 83655 | <1% | 147 | $2K | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 149 | $2K |
| 80179 | <1% | 115 | $2K | |
| 82043 | <1% | 265 | $2K | |
| 72040 | <1% | 60 | $2K | |
| 87070 | <1% | 161 | $2K | |
| 85651 | <1% | 350 | $2K | |
| Z9726 | <1% | 40 | $2K | |
| 84100 | <1% | 275 | $2K | |
| 74021 | <1% | 49 | $2K | |
| 72072 | <1% | 36 | $2K | |
| 82248 | <1% | 209 | $2K | |
| 73590 | <1% | 38 | $1K | |
| J2358 | Injection, olanzapine, long-acting, 1 mg | <1% | 91 | $1K |
| 99283 | Emergency room visit (moderate) | <1% | 25 | $1K |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 131 | $1K |
| 76775 | <1% | 14 | $1K | |
| 76881 | <1% | 15 | $946.96 | |
| 84439 | <1% | 81 | $944.17 | |
| 73090 | <1% | 31 | $858.19 | |
| 96523 | <1% | 38 | $831.54 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 66 | $678.76 |
| 87806 | <1% | 15 | $609.45 | |
| 84550 | <1% | 92 | $553.94 | |
| Z7500 | <1% | 15 | $511.50 | |
| J3410 | Injection, hydroxyzine hcl, up to 25 mg | <1% | 15 | $481.92 |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 13 | $407.00 |
| 82150 | <1% | 44 | $362.49 | |
| 82550 | <1% | 49 | $355.30 | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 42 | $347.56 |
| 84145 | <1% | 12 | $344.30 | |
| 85027 | <1% | 38 | $334.07 | |
| 87147 | <1% | 27 | $323.89 | |
| 73560 | <1% | 12 | $292.71 | |
| 97014 | <1% | 66 | $259.37 | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 42 | $257.56 |
| 73660 | <1% | 12 | $247.17 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 30 | $240.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 123 | $180.02 |
| J3490 | Unclassified drugs | <1% | 33 | $179.33 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 117 | $174.63 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 13 | $139.08 |
| 84703 | <1% | 12 | $128.26 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 13 | $119.56 |
| 96379 | <1% | 1,396 | $106.99 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 12 | $0.00 |
| 36415 | Collection of venous blood by venipuncture | 0% | 88 | $0.00 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRICHARDSON, TARA (VP PATIENT FINANCIAL SERVICES)
| Provider | Location | Paid |
|---|---|---|
| Granite City Illinois Hospital Company LLC | Granite City, IL | $1.09M |
| DHSC LLC | Massillon, OH | $186K |
| Big Bend Hospital Corporation | Alpine, TX | $177K |
| National Healthcare of MT Vernon INC | Mount Vernon, IL | $105K |
| Galesburg Hospital Corporation | Galesburg, IL | $99K |
| Centre Hospital Corporation | Centre, AL | $30K |
| Jackson Hospital Corporation | Campton, KY | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.